Neurotech Pharmaceuticals

[{"orgOrder":0,"company":"Neurotech Pharmaceuticals","sponsor":"The Lowy Medical Research Institute Limited | The Emmes Company, LLC","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2013","type":"Inapplicable","leadProduct":"Ciliary Neurotrophic Factor","moa":"atropine derivatives","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Neurotech Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Neurotech Pharmaceuticals \/ The Lowy Medical Research Institute Limited | The Emmes Company, LLC","highestDevelopmentStatusID":"8","companyTruncated":"Neurotech Pharmaceuticals \/ The Lowy Medical Research Institute Limited | The Emmes Company, LLC"},{"orgOrder":0,"company":"Neurotech Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2017","type":"Inapplicable","leadProduct":"Ciliary Neurotrophic Factor","moa":"atropine derivatives","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Neurotech Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Neurotech Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Neurotech Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Neurotech Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"NT-501","moa":"atropine derivatives","graph1":"Rare Diseases and Disorders","graph2":"Phase IV","graph3":"Neurotech Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Neurotech Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Neurotech Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Neurotech Pharmaceuticals","sponsor":"The Lowy Medical Research Institute Limited","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2017","type":"Inapplicable","leadProduct":"NT-501","moa":"atropine derivatives","graph1":"Rare Diseases and Disorders","graph2":"Phase IV","graph3":"Neurotech Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Neurotech Pharmaceuticals \/ The Lowy Medical Research Institute Limited","highestDevelopmentStatusID":"11","companyTruncated":"Neurotech Pharmaceuticals \/ The Lowy Medical Research Institute Limited"},{"orgOrder":0,"company":"Neurotech Pharmaceuticals","sponsor":"The Lowy Medical Research Institute Limited","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2017","type":"Inapplicable","leadProduct":"NT-501","moa":"atropine derivatives","graph1":"Rare Diseases and Disorders","graph2":"Phase IV","graph3":"Neurotech Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Neurotech Pharmaceuticals \/ The Lowy Medical Research Institute Limited","highestDevelopmentStatusID":"11","companyTruncated":"Neurotech Pharmaceuticals \/ The Lowy Medical Research Institute Limited"},{"orgOrder":0,"company":"Neurotech Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"NT-501","moa":"atropine derivatives","graph1":"Rare Diseases and Disorders","graph2":"Phase IV","graph3":"Neurotech Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Neurotech Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Neurotech Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Neurotech Pharmaceuticals","sponsor":"University of California, San Francisco","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2012","type":"Inapplicable","leadProduct":"NT-501","moa":"atropine derivatives","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Neurotech Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Implant","sponsorNew":"Neurotech Pharmaceuticals \/ University of California, San Francisco","highestDevelopmentStatusID":"8","companyTruncated":"Neurotech Pharmaceuticals \/ University of California, San Francisco"},{"orgOrder":0,"company":"Neurotech Pharmaceuticals","sponsor":"The Lowy Medical Research Institute Limited","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"NT-501","moa":"atropine derivatives","graph1":"Rare Diseases and Disorders","graph2":"Phase IV","graph3":"Neurotech Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Neurotech Pharmaceuticals \/ The Lowy Medical Research Institute Limited","highestDevelopmentStatusID":"11","companyTruncated":"Neurotech Pharmaceuticals \/ The Lowy Medical Research Institute Limited"},{"orgOrder":0,"company":"Neurotech Pharmaceuticals","sponsor":"The Lowy Medical Research Institute Limited","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2011","type":"Inapplicable","leadProduct":"NT-501","moa":"atropine derivatives","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Neurotech Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Neurotech Pharmaceuticals \/ The Lowy Medical Research Institute Limited","highestDevelopmentStatusID":"6","companyTruncated":"Neurotech Pharmaceuticals \/ The Lowy Medical Research Institute Limited"},{"orgOrder":0,"company":"Neurotech Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Revakinagene Taroretcel","moa":"CNTF","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Neurotech Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Neurotech Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Neurotech Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Neurotech Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Revakinagene Taroretcel","moa":"CNTF","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Neurotech Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Neurotech Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Neurotech Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Neurotech Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Revakinagene Taroretcel","moa":"CNTF","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Neurotech Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Neurotech Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Neurotech Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Neurotech Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Revakinagene Taroretcel","moa":"CNTF","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Neurotech Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Neurotech Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Neurotech Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Neurotech Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"NT-503-3","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Neurotech Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Neurotech Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Neurotech Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Neurotech Pharmaceuticals","sponsor":"AdvanCell","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"NT-KO-003","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Neurotech Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Neurotech Pharmaceuticals \/ AdvanCell","highestDevelopmentStatusID":"8","companyTruncated":"Neurotech Pharmaceuticals \/ AdvanCell"}]